Physician profile
Patrick S Osullivan
NPI 1265642482
$3,961.63
in general payments reported to CMS, 2019-2025
13 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $147 · 2021: $418 · 2022: $204 · 2023: $1,198 · 2024: $807 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $1,133.03 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $528.14 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $489.74 | 2019-2025 | Eylea Hd, Eylea |
| Coherus Oncology, INC. | $439.65 | 2023-2024 | |
| Genentech USA, INC. | $337.89 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $253.73 | 2019 | |
| Allergan, INC. | $203.91 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $174.47 | 2023-2024 | Syfovre |
| Biogen, INC. | $155.91 | 2023-2024 | Byooviz |
| Astellas Pharma US INC | $124.17 | 2023-2025 | Izervay |
| Sandoz INC. | $68.88 | 2024 | Cimerli |
| Ani Pharmaceuticals, INC. | $32.71 | 2025 | Yutiq |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Osullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.